Monoclonal Antibodies
FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region
[11/30/2022] The U.S. Food and Drug Administration today announced bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1., according to data included in the Health Care Provider Fact Sheet.
For more information, please click here.